OTCPK:THCT

Stock Analysis Report

Executive Summary

THC Therapeutics, Inc. focuses on the wellness industry.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has THC Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.7%

THCT

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

47.1%

THCT

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: THCT exceeded the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: THCT exceeded the US Market which returned 6.7% over the past year.


Share holder returns

THCTIndustryMarket
7 Day-12.7%-0.4%1.0%
30 Day19.0%-2.7%-1.8%
90 Day-37.5%-0.3%-1.8%
1 Year47.1%47.1%13.7%12.8%9.1%6.7%
3 Yearn/a70.0%64.8%46.1%36.6%
5 Yearn/a130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is THC Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is THC Therapeutics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether THC Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as THC Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of THCT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through THC Therapeutics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is THC Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of THCT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access THC Therapeutics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has THC Therapeutics performed over the past 5 years?

-2763.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: THCT is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare THCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: THCT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: THCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: THCT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: THCT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is THC Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: THCT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: THCT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: THCT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: THCT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: THCT has a high level of physical assets or inventory.

Debt Coverage by Assets: THCT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: THCT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: THCT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.2% each year


Next Steps

Dividend

What is THC Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate THCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate THCT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if THCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of THCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of THC Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average board tenure


CEO

Brandon Romanek (44yo)

2.8yrs

Tenure

0

Mr. Brandon Romanek serves as Chairman of the Board, Chief Executive Officer since January 2017, President, Chief Financial Officer and Secretary of THC Therapeutics, Inc., and has been its Director since  ...


Board Age and Tenure

1.7yrs

Average Tenure

Experienced Board: THCT's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Brandon Romanek (44yo)

    Chairman

    • Tenure: 2.8yrs

Board Members

  • Enzo Villani

    Director

    • Tenure: 0.5yrs
  • Cory Klippsten

    Member of Advisory Board

    • Tenure: 1.7yrs
  • Michael Terpin

    Chairman of the Advisory Board

    • Tenure: 1.8yrs
  • Brandon Romanek (44yo)

    Chairman

    • Tenure: 2.8yrs
  • Clifford Sarkin

    Member of Board of Advisors

    • Tenure: 1.8yrs

Company Information

THC Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: THC Therapeutics, Inc.
  • Ticker: THCT
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$29.403m
  • Shares outstanding: 14.70m
  • Website: https://thct.io

Number of Employees


Location

  • THC Therapeutics, Inc.
  • 645 Front Street
  • Suite 2202
  • San Diego
  • California
  • 92101
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
THCTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2017

Biography

THC Therapeutics, Inc. focuses on the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer. The company was formerly known as Millennium Blockchain, Inc. and changed ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:30
End of Day Share Price2019/10/11 00:00
Earnings2019/04/30
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)